Shots: The companies collaborated to evaluate the Evaxion’s EVX-01 + MSD’s Keytruda in P-IIb study in patients with metastatic melanoma stage III & IV. The trial is expected to start […]readmore
Tags : Metastatic Melanoma
Shots: The MAA was based on the efficacy & safety results from the P-II/III RELATIVITY-047 trial that evaluates the fixed-dose combination of relatlimab (160mg) + nivolumab (480mg) vs Opdivo (480mg, […]readmore
Shots: The P-1b/2 KEYNOTE-146/Study 111 trial involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg IV q3w) in patients with NSCLC, Advanced melanoma & urothelial cancer P1b/2 KEYNOTE-146/Study 111 […]readmore